ThermoGenesis has launched Res-Q 60 BMC (Res-Q) System, an automated cell processing medical device for the concentration of bone marrow-derived stem cells at the point of care.
The Res-Q System processes bone marrow and help deliver stem cell recovery. The Res-Q System follows the late 2008 launch of the MXP MarrowXpress (MXP) System, a laboratory device also used to collect stem cells from bone marrow.
Reportedly, the company plans to initially target the orthopedic regenerative medicine market through its orthopedic distribution partner Celling Technologies (Celling), a subsidiary of SpineSmith.
Melville Engle, CEO of ThermoGenesis, said: We are excited to add a new member to our stem cell processing product family to help us access the growing regenerative medicine market in a meaningful way. We believe our Res-Q System has considerable advantages over competing products and should help surgeons realize the true value of autologous cellular therapy.